1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Adenocarcinoma - Pipeline Review, H2 2013

Adenocarcinoma - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 90 pages

Adenocarcinoma - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Adenocarcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Adenocarcinoma. Adenocarcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Adenocarcinoma.
- A review of the Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Adenocarcinoma pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Adenocarcinoma - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Adenocarcinoma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Adenocarcinoma 9
Adenocarcinoma Therapeutics under Development by Companies 11
Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Pre-Clinical Stage Products 17
Comparative Analysis 17
Adenocarcinoma Therapeutics - Products under Development by Companies 18
Adenocarcinoma Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Adenocarcinoma Therapeutics Development 20
Boehringer Ingelheim GmbH 20
Sanofi-Aventis 21
Gilead Sciences, Inc. 22
Delcath Systems, Inc. 23
Lorus Therapeutics Inc 24
Peregrine Pharmaceuticals, Inc. 25
Morphotek, Inc. 26
MacroGenics, Inc. 27
Iconic Therapeutics, Inc. 28
Laboratorio Elea S.A.C.I.F. and A 29
Adenocarcinoma - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 37
LOR-1284 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Anti-Angiogenesis Agent 2C3 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
nintedanib - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
bavituximab - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
hI-con1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
melphalan - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
irofulven - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
PEG-BCT-100 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Cancer Macrobeads - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
CAP1-6D Vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
bevacizumab + [capecitabine] + [oxaliplatin] - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
cabazitaxel - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
simtuzumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
CIGB-300 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
HM-30181-A + paclitaxel - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
MGARG-2 - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
GnRHm1-TT - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
MORAb-066 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
PEI-DNA - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Autologous Dendritic Cell Vaccine - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
MCT-1 Inhibitors - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Adenocarcinoma Therapeutics - Drug Profile Updates 70
Adenocarcinoma Therapeutics - Discontinued Products 83
Adenocarcinoma Therapeutics - Dormant Products 84
Adenocarcinoma - Product Development Milestones 86
Featured News and Press Releases 86
May 15, 2013: Boehringer Ingelheim To Present Five Abstracts For Afatinib At ASCO 2013 86
Jul 16, 2012: Peregrine Initiates Phase I Rectal Adenocarcinoma Investigator Sponsored Trial 87
Mar 15, 2012: Bio-Cancer Treatment International Obtains FDA Approval To Initiate Phase I Study Of Cancer Drug PEG-BCT-100 88
Dec 31, 2010: Authorization for the clinical trial "TherGAP" 88
Apr 20, 2007: Certification for the "TherGAP" 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 90
Disclaimer 90

List of Tables

Number of Products Under Development for Adenocarcinoma, H2 2013 9
Products under Development for Adenocarcinoma - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Late Stage Development, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Boehringer Ingelheim GmbH, H2 2013 20
Sanofi-Aventis, H2 2013 21
Gilead Sciences, Inc., H2 2013 22
Delcath Systems, Inc., H2 2013 23
Lorus Therapeutics Inc, H2 2013 24
Peregrine Pharmaceuticals, Inc., H2 2013 25
Morphotek, Inc., H2 2013 26
MacroGenics, Inc., H2 2013 27
Iconic Therapeutics, Inc., H2 2013 28
Laboratorio Elea S.A.C.I.F. and A, H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Combination Products, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 36
Adenocarcinoma Therapeutics - Drug Profile Updates 70
Adenocarcinoma Therapeutics - Discontinued Products 83
Adenocarcinoma Therapeutics - Dormant Products 84
Adenocarcinoma Therapeutics - Dormant Products (Contd..1) 85

List of Figures

Number of Products under Development for Adenocarcinoma, H2 2013 9
Products under Development for Adenocarcinoma - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Late Stage Products, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 30
Assessment by Combination Products, H2 2013 31
Assessment by Route of Administration, H2 2013 32
Assessment by Stage and Route of Administration, H2 2013 33
Assessment by Molecule Type, H2 2013 34
Assessment by Stage and Molecule Type, H2 2013 35

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.